Cyllene Therapeutics Raises €33 Million Series C
By Amit Chowdhry ● Jul 8, 2026
Cyllene Therapeutics announced the closing of a €33 million Series C financing round. The company was formerly known as EG 427 and rebranded to Cyllene Therapeutics alongside the financing. The round was co-led by GordonMD Global Investments and Merck Ventures, an affiliate of Merck KGaA, Darmstadt, Germany. T. Andera Partners, Bpifrance Investissement through its InnoBio 3 Fund, and Lamond Ventures also participated.